Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

65°
- Benton, AR (72018)
  Today
  
  Lots of sunshine. High 64F. Winds S at 10 to 15 mph..
  
  Tonight
  
  Partly cloudy skies this evening will become overcast overnight. Low 53F. Winds SSW at 5 to 10 mph.
  
  Updated: January 5, 2026 @ 2:29 pm
- Full Forecast

- Site search

Home
News
- Local News
Sports
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Archives
Readers Choice 2025

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

21.34 -0.59 (-2.67%)

Streaming Delayed Price Updated: 3:55 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 Next >

Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day

December 11, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

November 10, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

October 27, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

September 17, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List

September 11, 2025

From Roivant Sciences

Via GlobeNewswire

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

September 04, 2025

From Pulmovant, Inc.

Via GlobeNewswire

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

September 03, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

August 11, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

July 28, 2025

From Roivant Sciences

Via GlobeNewswire

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

June 16, 2025

From Pulmovant, Inc.

Via GlobeNewswire

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

June 09, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

May 29, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

May 15, 2025

From Roivant Sciences

Via GlobeNewswire

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

April 21, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

March 19, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

March 18, 2025

From Roivant Sciences

Via GlobeNewswire

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

March 03, 2025

From Arbutus Biopharma Corporation

Via GlobeNewswire

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

February 10, 2025

From Roivant Sciences

Via GlobeNewswire

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

February 03, 2025

Zest is initially focused on treating the millions of Americans with inflammatory skin diseases who are currently overprescribed expensive biologics

From Roivant Sciences

Via GlobeNewswire

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

January 29, 2025

From Roivant Sciences

Via GlobeNewswire

Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

December 03, 2024

From Roivant Sciences

Via GlobeNewswire

Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

December 03, 2024

From Roivant Sciences

Via GlobeNewswire

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update

November 12, 2024

From Roivant Sciences

Via GlobeNewswire

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

October 29, 2024

From Roivant Sciences

Via GlobeNewswire

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

October 28, 2024

The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.

From Roivant Sciences

Via GlobeNewswire

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

September 18, 2024

From Roivant Sciences

Via GlobeNewswire

Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress

September 10, 2024

From Roivant Sciences

Via GlobeNewswire

Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

September 10, 2024

From Roivant Sciences

Via GlobeNewswire

Roivant Provides Update on Graves’ Disease Development Program

September 09, 2024

From Roivant Sciences

Via GlobeNewswire

Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update

August 08, 2024

From Roivant Sciences

Via GlobeNewswire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

bentoncourier.com
321 North Market Street
Benton, AR 72018
Phone: 501-315-8228
Email: bcadmin@bentoncourier.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Benton, AR (72018)

Today

Tonight

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

Press Releases about Roivant Sciences Ltd. - Common Shares

Sections

Services

Follow Us